Sapphyrins are pentapyrrolic, metal-free, expanded porphyrins.
Introduction
Sapphyrins are pentapyrrolic metal-free expanded porphyrins with potential medical utility (1) . Sapphyrins bind to anions such as phosphate, chloride, and fluoride and have been postulated to serve as potential anion transporters (1 -3) . Sapphyrins absorb light in the red portion of the visible spectrum and can generate singlet oxygen in good quantum yield (4 -7) . Sapphyrins have been explored as potential photodynamic therapy agents to inactivate viruses in vitro and also to treat superficial squamous cell carcinoma in mice (5, 6) . Like porphyrins, some sapphyrins show tumor localization (4, 8) . Such considerations, coupled with a recognition that the chemical, electrochemical, and supramolecular properties of sapphyrins can differ dramatically from those of porphyrins, have led to the idea that they might display useful anticancer properties even in the absence of light, ionizing radiation, or other activating factors. Recently, Král et al. (9) reported that a sapphyrin derivative was cytotoxic to Jurkat cells in tissue culture and suggested that sapphyrins or other porphyrin-like systems might display useful anticancer properties even in the absence of light. However, no systematic in vitro or in vivo study of the inherent antineoplastic properties of sapphyrins has appeared.
In the present study, we show that water-soluble sapphyrins, such as the bis-hydroxypropyl derivative PCI-2000, can act as potent inducers of apoptosis in a wide variety of hematopoietic tumor -derived cell lines including lymphoma, leukemia, and myeloma. The water-soluble sapphyrin, PCI-2000, was found to trigger an apoptotic pathway in the tumor cells as shown by release of cytochrome c from mitochondria; activation of caspases 9, 8, and 3; cleavage of the caspase-3 substrate poly(ADPribose) polymerase; and Annexin V binding. Treatment with this sapphyrin or PCI-2010, a congeneric tetrahydroxy biscarbamate derivative, resulted in enhanced phosphorylation of p38 mitogen-activated protein kinase (MAPK), a stressresponsive protein kinase that participates in the regulation of apoptosis. Both of these sapphyrins were found to have potent cytotoxic activity in hematopoietic-derived tumor cells, with PCI-2010 displaying a lower level of toxicity in mice. Accordingly, PCI-2010 activity was studied in vivo and it was found to inhibit the growth of Ramos and HL-60 cells in mouse xenograft models. On the basis of these findings, we suggest that these and other sapphryins warrant further evaluation as potential investigational new drug candidates for the treatment of cancer.
Materials and Methods
Sapphyrin Synthesis PCI-2000 was prepared using the ''3 + 1 + 1'' procedure as described in the literature (10). PCI-2010 was synthesized from PCI-2000 through the use of an active carbonate method (see Fig. 1 for chemical structures) . Briefly, PCI-2000 (1 mmol) was treated with disuccinimidyl carbonate (5 mmol; Sigma-Aldrich, St. Louis, MO) in the presence of diisopropylethylamine (10 mmol) in anhydrous methylene chloride for 1 hour. The active carbonate intermediate was then reacted with diethanolamine (10 mmol) for 4 hours. Both reaction steps were carried out at room temperature. After the reaction was complete, the product was purified by flash chromatography on neutral alumina followed by column chromatography with tC18 Sep-Pak (Waters, Milford, MA). The purity of the final product was >94% as measured by reversed-phase high-performance liquid chromatography. The identity was ascertained by proton and carbon-13 nuclear magnetic resonance spectra, as well as by electrospray ionization mass spectrometry. PCI-2000 and PCI-2010 were formulated in 100% DMSO for the in vitro studies. For animal studies, PCI-2000 was formulated by dissolving in 5% mannitol containing 5% absolute ethanol followed by sterile filtration, whereas PCI-2010 was formulated by dissolving in 5% mannitol followed by sterile filtration.
Cell Lines and Growth Conditions All cell lines were grown in RPMI 1640 with 10% fetal bovine serum in a 5% CO 2 /air incubator at 37jC. Cells at a density of 100,000 cells/mL were treated with sapphyrins for 24 or 96 hours and then assessed for apoptosis. Final DMSO concentrations in cell cultures were generally V0.02% and control experiments showed that DMSO concentrations used in this study had no effect on cell viability or growth. Cell numbers were determined using a model Z2 counter (Beckman-Coulter, Miami, FL).
Addition of sapphyrins to tissue culture cells was done under subdued lighting and sapphyrin-treated cells were cultured in a dark incubator to minimize any possibility of cytotoxicity stemming from light exposure. Control experiments showed no enhancement of cell death in PCI-2000 -or PCI-2010 -treated cultures resulting from intentional exposure to bright fluorescent lighting for 1 minute.
Apoptosis Assays Annexin V-FITC binding and propidium iodide exclusion were assayed with a FACSCalibur instrument (Becton Dickinson, San Jose, CA) using reagents from Biosource (Camarillo, CA) per protocol of the manufacturer.
Caspase-3 activity was assayed using the EnzChek Caspase-3 Assay Kit #2 (Molecular Probes, Eugene, OR). Cells were harvested, rinsed in cold PBS, and analyzed according to the protocol of the manufacturer. Cell extracts were incubated in a reaction mixture containing Z-DEVD-R110 (0.5 mmol/L) at room temperature for 30 minutes, and fluorescence levels were determined at an excitation of 485 nm and emission of 510 nm using a fluorescence plate reader. For each cell line, measured fluorescence levels were normalized to fluorescence levels of nontreated cell lysates.
Release of Cytochrome c from Mitochondria
The distribution of cytochrome c in the cytoplasm and pellet containing mitochondria was determined using Western blotting after Dounce homogenization and differential centrifugation of sapphyrin-treated and control cells. Mouse anti -cytochrome c antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was used to detect cytochrome c, and mouse monoclonal antibody to cytochrome c oxidase II, a protein found in the inner mitochondrial membrane, was used to track the mitochondrial fraction (Cell Signaling Technologies, Inc., Beverly, MA).
Western Blotting Cells were lysed in triple-detergent lysis buffer [50 mmol/L Tris-Cl (pH 8.0), 150 mmol/L NaCl, 0.1% SDS, 0.5% deoxycholic acid, 1.0% NP40, supplemented with 100 Amol/L phenylmethylsulfonyl fluoride and Complete Protease Inhibitor Cocktail (Roche Molecular Biochemicals, Indiannapolis, IN)] on ice for 10 minutes. After centrifugation at 10,000 Â g for 10 minutes, the supernatants were analyzed for protein concentration, with equal amounts of protein being resolved on SDS-polyacrylamide gels (BioRad, Hercules, CA). The gels were transferred to a polyvinylidene difluoride membrane using a Semi-dry Transfer Cell (Bio-Rad). Antibodies to caspases and poly(ADP-ribose) polymerase were used, which specifically recognized the full-length and cleaved forms of their respective antigens (Cell Signaling Technologies). Antibodies to p38 MAPK and phosphorylated p38 MAPK (both antibodies recognize all four isoforms) were obtained from Cell Signaling Technology. All membranes were blotted with antibodies for loading controls. Protein bands were imaged and quantified in the linear range and normalized to control proteins using the Odyssey Infrared Imaging System (LI-COR, Lincoln, NE). 
PCI-2000 Induces Release of Cytochrome c from Mitochondria
Many chemotherapy drugs affect the mitochondrial pathway of apoptosis by releasing cytochrome c, which then activates a caspase cascade through the formation of a complex with apoptotic protease activating factor 1 and caspase-9, thereby resulting in autocleavage of caspase-9 (11). To determine if mitochondria are involved in sapphyrin-induced apoptosis, Ramos cells were treated with PCI-2000 (1 Amol/L for 16 hours) and fractionated into soluble and membrane (including mitochondria) fractions. In carrier vehicle-treated cells (DMSO), most of the cytochrome c was found in the membrane fraction. In cells treated with PCI-2000, more cytochrome c was found in the soluble fraction, leading to the conclusion that it had been released from the mitochondria (Fig. 4) .
Activation of Caspases 9, 3, and 8 in PCI-2000T reated Cells There are two primary pathways for caspase activation-one triggered by receptor activation on the cell surface and the other by mitochondrial damage (11, 12) . (Fig. 5A) . To determine which caspases were activated, cells were harvested and protein subjected to Western blotting to monitor cleavage (activation) of caspases 9, 3, and 8 and the substrate poly(ADP-ribose) polymerase. Consistent with activation of the mitochondrial pathway, caspase-9 was activated early followed by caspase-3 (Fig. 5B) . Caspase-3 (a downstream target of caspase-9) was cleaved as was the caspase-3 substrate poly(ADP-ribose) polymerase (Fig. 5B) . Caspase-8 cleavage occurred after cleavage of caspases 9 and 3, consistent with a potential feedback loop from caspase-3 resulting in caspase-8 cleavage ( Fig. 5B; ref. 13 ).
Overexpression of Bcl-2 or Inhibition of Caspase Activity Blocks PCI-2000^Induced Apoptosis
One function of Bcl-2, an oncogene with antiapoptotic properties, is to block the activity of Bcl-2 homology domain 3-only members to release cytochrome c from mitochondria (14) . We hypothesized that Bcl-2, through inhibition of cytochrome c release, could potentially inhibit sapphyrininduced apoptosis. To test this hypothesis, wild-type HL-60 cells and HL-60 cells overexpressing Bcl-2 were treated with 1 Amol/L PCI-2000 (15) . Overexpression of Bcl-2 resulted in fewer Annexin V -positive cells and less caspase-3 activity compared with the control cell line (Fig. 6 A and B) . Although Bcl-2 inhibited apoptosis in PCI-2000 -treated cells, Bcl-2 did not circumvent the growth inhibition caused by PCI-2000 (Fig. 6C) . These results show that HL-60 cells resistant to sapphyrin-induced apoptosis through Bcl-2 overexpression are still growth inhibited.
Caspase activation leads to the morphologic and biochemical changes associated with apoptosis (16). To (Fig. 6D) . These results show that PCI-2000 triggers the caspase pathway resulting in caspase-dependent apoptosis.
SapphyrinTreatment Results in Increased Phosphorylation of p38 MAPK During the course of this study, PCI-2010, a tetrahydroxy bis-carbamate derivative of PCI-2000, was synthesized and evaluated for cytotoxicity. PCI-2010 was found to be as efficacious as PCI-2000 in inducing apoptosis in Ramos cells as shown by Annexin V and caspase activity assays ( Fig. 7A and B) . PCI-2010 treatment also resulted in caspase cleavage and poly(ADP-ribose) polymerase cleavage (data not shown).
p38 MAPKs are protein kinases that are activated (phosphorylated) by a wide variety of stress-inducing stimuli including chemotherapy, DNA damage, and oxidative stress (17, 18) . To determine if sapphyrins activated p38 MAPK, we treated Ramos cells with increasing doses of PCI-2000 and PCI-2010 for 8 hours and did analysis for phosphorylated p38 and total p38 MAPK. Both PCI-2000 and PCI-2010 resulted in increased levels of phosphorylated p38 MAPK (Fig. 7C) . Activation of the p38 MAPK pathway through phosphorylation may be either proapoptotic or antiapoptotic depending on cell types and conditions (18) . To determine the relevance of p38 phosphorylation to sapphyrin-induced cytotoxicity, we treated Ramos cells with PCI-2000 and an inhibitor of p38 phosphorylation, SB 203580. We found that the inhibitor alone was not cytotoxic but stimulated the cytotoxicity of PCI-2000 (Fig. 7D) . For example, PCI-2000 at 1 Amol/L resulted in 26.9% Annexin V -positive cells but combined treatment with PCI-2000 and the p38 phosphorylation inhibitor resulted in 60.5% Annexin Vpositive cells (Fig. 7D) . PCI-2000 used at 1.5 Amol/L essentially saturated the Annexin assay (91.8% dead cells) and, therefore, when combined with SB 203580, only showed a minor increase in cell death (to 98.3%; Fig. 7D ). Analysis of the data set with the CalcuSyn program revealed a combination index of <1, which is indicative of a synergistic interaction (Fig. 7E) . We also showed that SB 203580 inhibited the sapphyrin-induced phosphorylation of p38 MAPK (Fig. 7F) . These results suggest that p38 MAPK phosphorylation protects against the cytotoxic effects of sapphyrins. We found that sapphyrins did not result in the phosphorylation of extracellular signalregulated kinases, which are mainly activated by growth factors (data not shown; refs. 17, 18) .
PCI-2010 Is Active in Xenograft Tumor Models
Single-dose toxicity studies showed that PCI-2010 had a higher lethal dose in mice than did PCI-2000 (Table 1 ).
Because PCI-2000 and PCI-2010 have approximately equivalent in vitro apoptosis-inducing activity, PCI-2010 was selected for further in vivo study to determine efficacy in two different animal models. The first was a minimal disease model, wherein Ramos xenograft -bearing animals were treated with PCI-2010 (20 Amol/kg daily for two doses) or vehicle control (5% mannitol) before development of palpable tumors. In this model, animals treated with PCI-2010 showed a substantial delay in tumor growth compared with the vehicle-treated animals (Fig. 8A) . Comparison of mean tumor volumes in controls and PCI-2010 -treated animals using a Student's t test (assuming equal variances) revealed a significant difference (P < 0.05) beginning on day 5 through study completion. As a further demonstration of efficacy, a second, palpable (Fig. 8B) . Tumors in control animals were significantly different from those in PCI-2010 -treated animals (P < 0.05) beginning on treatment day 17 through study completion.
Discussion
Porphyrins and expanded porphyrins such as texaphyrins and sapphyrins have potential medical utility, including cancer imaging and therapy (1, 19, 20) . For instance, the porphyrin mixture, porfimer sodium, is a drug used for the treatment of esophageal and endobronchial lung cancer via photodynamic therapy (19) . Sapphyrins are expanded metal-free porphyrins with interesting chemical properties. However, only limited information is available regarding their biological activity. Like porphyrins, sapphyrins are known to localize to tumor tissues through mechanisms that are not understood (8) . Sapphyrins have been investigated in the context of photodynamic therapy (5, 6) . One sapphyrin has been previously reported to exhibit cytotoxic activity in the absence of photoactivating light (9) . In that study, which was focused primarily on the biological activity of a pentapyrrolic expanded porphyrin termed pentaphyrin, only the inhibitory dose (ID 50 ) for Jurkat cells was presented and only for one particular sapphyrin. To the best of our knowledge, there has been no follow-up article published and no other report on the biological activity manifested by sapphyrins in the absence of light. We sought to evaluate the antitumor properties of sapphyrins based on their reported ability to concentrate in neoplastic tissues (8) . In this study, we describe the cytotoxic (PCI-2000 and PCI-2010) and antitumor (PCI-2010) activities of sapphyrins that justify their further study as potential anticancer agents. We showed that sapphyrins induce apoptosis in numerous cell lines including those derived from lymphoma, leukemia, and multiple myeloma in the absence of sufficient light to induce photodynamic effects. The biochemical pathway through which sapphyrins induce apoptosis has not yet been fully elucidated. Similar to other stress-inducing stimuli, sapphyrin treatment results in the phosphorylation of p38 MAPK, which may then transduce either survival or death signals (17, 18) . The combination of PCI-2000 with a specific inhibitor of p38 MAPK phosphorylation resulted in synergistic cytotoxicity, suggesting that p38 MAPK phosphorylation was protective in PCI-2000 -treated Ramos cells. A similar situation has been described with bortezomib, a proteasome inhibitor that is used in the treatment of multiple myeloma. Bortezomib induces the phosphorylation of p38 MAPK, and inhibition of p38 MAPK phosphorylation enhances bortezomib-induced cytotoxicity (21) . The synergistic combination of a sapphyrin and a p38 MAPK phosphorylation inhibitor may someday be clinically relevant.
Sapphyrins activate the mitochondrial pathway of apoptosis as shown by release of cytochrome c from mitochondria and cleavage of caspase-9. Interestingly, sapphyrins have been shown to interact directly with isolated mitochondria in an in vitro system (22) . Future studies will determine if sapphyrins localize to mitochondria in intact cells. Overexpression of Bcl-2, a protein that modulates mitochondrial-mediated apoptosis through binding of Bcl-2 homology domain 3 proteins, inhibits sapphyrin-induced apoptosis but not growth inhibition. Therefore, like many other cytotoxic agents, sapphyrin acts upstream of Bcl-2 to trigger an apoptotic pathway. Regardless of the mechanism(s) used to trigger mitochondrial release of cytochrome c, sapphyrins activate a caspase cascade that results in cell death in the absence of Bcl-2 overexpression. Sapphyrin-induced apoptosis is caspase dependent because an inhibitor of caspases (z-VAD-fmk) blocks apoptosis. The ability of sapphyrins to induce apoptosis is not limited to hematopoietic tumor -derived cell lines because they also induce apoptosis in solid tumorderived cell lines. 3 In an effort to ascertain whether sapphyrins warrant further consideration as potential anticancer agents, their toxicity profiles in normal mice were determined and their efficacy in mouse tumor models was assessed. Single injections of escalating doses of PCI-2000 and PCI-2010, followed by observation for morbidity and mortality and histologic examination, revealed that PCI-2010 had a more acceptable toxicity profile than PCI-2000. There was no decrease in the peripheral WBC count, RBC count, or platelet count in sapphyrin-treated mice, suggesting that bone marrow suppression is not a prominent side affect of sapphyrins. 4 We focused our tumor efficacy studies on PCI-2010 exclusively because it was found to be better tolerated in mice than PCI-2000. As detailed in Results, PCI-2010 was found to delay tumor growth in two different xenograft models, a Ramos xenograft minimal disease model and an HL-60 palpable tumor model. As yet, we have not done sufficient experiments to determine the optimal dosing regimens. Nonetheless, the experiments done to date serve to highlight the fact that sapphyrins such as PCI-2010 may have a role to play as potential anticancer agents. This class of compounds is particularly attractive 
